Cigna Settles FTC Lawsuit Alleging It Inflated Insulin Costs (2)

Feb. 4, 2026, 6:06 PM UTC

Cigna Group’s Express Scripts reached a settlement with federal antitrust enforcers to resolve allegations that the company artificially inflated the price of insulin for patients through illegal rebate tactics.

The Federal Trade Commission — which filed suit in 2024 — said in a statement Wednesday that Express Scripts would change how it calculates prices for its list of approved drugs. Cigna is one of three pharmacy benefit managers that together control about 80% of prescriptions filled in the US.

The lawsuit against the other two companies, units of CVS Health Corp. and UnitedHealth Group Inc., remains ongoing. Last month, ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.